Heron Therapeutics (HRTX) vs NeOnc Technologies (NTHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Heron Therapeutics (HRTX) has outperformed NeOnc Technologies (NTHI) over the past year, losing 73.5% versus a loss of 79.1%. NeOnc Technologies is the larger company by market cap ($78.9 million vs $75.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRTX | NTHI |
|---|---|---|
| Share price | $0.3999 | $2.74 |
| Market cap | $75.92M | $78.93M |
| 1-day change | +11.64% | +8.33% |
| YTD return | -72.45% | -69.41% |
| 1-year return | -73.47% | -79.07% |
| 5-year return | -96.62% | — |
| EPS (TTM) | $-0.18 | $-2.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.58 | $12.09 |
| 52-week low | $0.26 | $2.50 |
| Distance from 52-week high | -74.69% | -77.34% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1650.44% | +520.44% |
| Average volume | 2.59M | 195.17K |
| Shares outstanding | 189.85M | 28.81M |
| Employees | 128 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Heron Therapeutics
HRTX stock →Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
HRTX vs NTHI FAQ
Which is bigger, Heron Therapeutics or NeOnc Technologies?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $78.93M compared with $75.92M for Heron Therapeutics (HRTX).
Which stock has performed better over the past year, HRTX or NTHI?
HRTX returned -73.47% over the past 12 months, compared with -79.07% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are Heron Therapeutics and NeOnc Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.